136248-40-3

Upstream product

• 157731-84-5 (Z)-2-[(2S,3S)-3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-2-methanesulfonyloxymethyl-4-oxo-azetidin-1-yl]-3-(toluene-4-sulfonyloxy)-but-2-enoic acid benzhydryl ester 
• 136302-55-1 (6S,7S)-7-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-8-oxo-3-([1,2,3]thiadiazol-5-ylsulfanylmethyl)-4-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 157731-85-6 (6S,7S)-3-Bromomethyl-7-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-8-oxo-4-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 136248-53-8 (6S,7S)-7-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-8-oxo-4-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 157731-88-9 (6S,7S)-7-Amino-8-oxo-3-([1,2,3]thiadiazol-5-ylsulfanylmethyl)-4-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 114875-61-5 (Z)-2-(((1,5-bis(benzhydryloxy)-4-oxo-1,4-dihydropyridin-2-yl)methoxy)imino)-2-(2-(tritylamino)thiazol-4-yl)acetic acid 

Relevant academic research and scientific papers

Synthesis and Structure-Activity relationships of cephalosporins, 2-isocephems, and 2-oxaisocephems with C-3' or C-7 catechol or related aromatics

A series of cephalosporins, 2-isocephems, and 2-oxaisocephems with C-3' catechol-containing (pyridinium-4-thio)methyl groups and 2-isocephems with C-7 catechol related aromatics have been prepared and evaluated for antimicrobial activity. It turns out that these compounds have highly potent activity against Gram-negative bacteria, especially resistant pathogens such as Pseudomonas aeruginosa. The most active compound of the series was (6S,7S)-7-[2-(2-aminothiazol-4-yl)-2-[(Z)-[(1,5-dihydroxy- 4-pyridon-2-yl)methoxy]imino]acetamido]-3-[[[(4-methyl-5- carboxymethyl)thiazol-2-yl]thio] methyl]-8-oxo-1-aza-4-thiabicyclo [4.2.0]-aza-4-thiabicyclo [4.2.0] oct-2-ene-2-carboxylic acid which exhibited potent in vitro activity against clinically isolated P. aeruginosa and Acinetobacter baumanii which is also resistant to many anti-infectives, and good in vivo efficacy against clinically isolated P aeruginosa.